TrialPharmacology research & perspectives2023

A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab.

C Schwabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.